Login to Your Account



Deals And M&A NEWS

One day after Sen. Bernie Sanders and Rep. Elijah Cummings penned a four-page letter to the FDA, about last month's approval of Emflaza, the drug's sponsor, Marathon Pharmaceuticals LLC, agreed to sell the drug to PTC Therapeutics Inc.

Allergan plc has agreed to front the genome editing company Editas Medicine Inc. $90 million plus potential milestone payments for an exclusive option to license up to five ocular programs during a seven-year term.

DUBLIN – Sanofi SA is paying €120 million up front and could pay up to €495 million more in development and commercial milestones for a 50 percent share in the economics of Astrazeneca plc's MEDI8897.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: